Table 4 Univariate and multivariate analyses for overall survival.
Variables | Category | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|
HR | 95% CI | P | HR | 95% CI | P | ||
Age, years | ≥ 65 (vs. < 65) | 1.05 | 0.70–1.57 | 0.830 | |||
Sex | Male (vs. female) | 0.70 | 0.46–1.08 | 0.105 | 0.84 | 0.52–1.36 | 0.475 |
ECOG PS | ≥ 1 (vs. 0) | 2.93 | 1.84–4.67 | < 0.001 | 2.90 | 1.75–4.79 | < 0.001 |
Histology | Diffuse (vs. intestinal) | 1.40 | 0.93–2.12 | 0.112 | 1.05 | 0.65–1.68 | 0.848 |
History of gastrectomy | Yes (vs. no) | 1.27 | 0.84–1.93 | 0.259 | |||
Lymph node metastasis | Yes (vs. no) | 0.94 | 0.62–1.41 | 0.763 | |||
Liver metastasis | Yes (vs. no) | 0.69 | 0.45–1.07 | 0.100 | 1.03 | 0.57–1.86 | 0.925 |
Peritoneal metastasis | Yes (vs. no) | 1.70 | 1.12–2.57 | 0.013 | 1.41 | 0.80–2.48 | 0.239 |
Number of metastatic sites | ≥ 2 (vs. 1) | 1.15 | 0.74–1.78 | 0.530 | |||
Number of prior regimens | ≥ 3 (vs. 1–2) | 0.78 | 0.44–1.39 | 0.405 | |||
Duration of prior ramucirumab | ≥ 3 months (vs. < 3 months) | 0.74 | 0.48–1.14 | 0.165 | 0.73 | 0.45–1.16 | 0.182 |
Ramucirumab-free interval | ≥ 3 months (vs. < 3 months) | 0.75 | 0.49–1.15 | 0.188 | 0.80 | 0.50–1.29 | 0.358 |
Anti-PD-1 inhibitor-free interval | < 60 days (vs. ≥ 60 days) | 0.84 | 0.56–1.25 | 0.391 | |||
Chemotherapy | FTD/TPI plus ramucirumab (vs. FTD/TPI) | 0.68 | 0.44–1.07 | 0.093 | 0.97 | 0.60–1.58 | 0.913 |
